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Peripheral Vascular Intervention Requires
New Ways to Look at CostsWe appreciate the opportunity to respond to a letter
written by Dr. Carr regarding our article published in
the Journal in March 2015 (1). We believe our
methods, results, and interpretation were a balanced,
descriptive report of current trends and the landscape
of peripheral vascular intervention (PVI) in the
U.S. Medicare population. Our main ﬁndings include:
1) a stabilization in the rate of PVIs in the United
States and a shift in care location from inpatient
settings to outpatient settings and ofﬁce-based
clinics; 2) increasing numbers of atherectomy pro-
cedures, which are associated with higher Medicare
expenditures than angioplasty and stenting pro-
cedures; and 3) the likelihood of neutralization of
cost savings for Medicare due to more expensive
procedures.
We would like to address Dr. Carr’s points of
clariﬁcation directly. First, our primary intent in
highlighting the increase in atherectomy procedures
in ofﬁce-based clinics was actually due to the fact
that changes to the Outpatient Prospective Payment
System (OPPS) occurred in 2008 and that theseprocedures were reimbursed by Medicare after that
time, a point seemingly similar to that stated by
Dr. Carr. Our further emphasis on the increase in
atherectomy was based on the increased costs to
Medicare and the limited evidence supporting its
use, therefore we think that this focus was
warranted.
Second, mean costs in our analysis were derived
from the sum of expenditures by Medicare and by
Medicare beneﬁciaries. These data were thoroughly
investigated, and in the online supplement, these
costs were reported separately for atherectomy alone
and for atherectomy plus stenting. We believe our
conclusions that atherectomy procedures were asso-
ciated with higher costs to Medicare and to Medicare
beneﬁciaries than those with stenting or angioplasty
procedures are ﬁrm.
Third, our analysis purposefully eliminated surgi-
cal revascularization procedures as there had been a
well-documented reduction in surgical revasculari-
zation over the past 2 decades, an occurrence that
pre-dated the changes to the OPPS (2,3). Our primary
intent was to evaluate the impact of changes in
OPPS, and because endovascular revascularization
was more commonly performed in outpatient settings
(and surgical revascularization was infrequently per-
formed in outpatient settings), we thought that the
impact of the changes in OPPS on the trends and costs
of endovascular revascularization would be more
apparent.
Fourth, although we agree that patients in our
study who received atherectomy appear to be
sicker than those patients undergoing angioplasty
or stenting, there is no evidence that atherectomy
is more effective for patients with critical limb
ischemia, as Dr. Carr states. We also disagree with
Dr. Carr that “differences in patient populations
could also indicate an improved access to care
(i.e., patients were treated who would otherwise
have been treated surgically or who would not
have undergone revascularization at all).” In fact,
these data are limited by an inability to evaluate
whether access to care was affected by the changes
in OPPS.
Fifth, we highlighted the paucity of data support-
ing use of atherectomy because we think that more
studies are needed in PAD patients to guide decision
making. We also do not think that Dr. Carr’s state-
ment that “[D]ata clearly demonstrate that PTA alone
in the femoropopliteal artery segment is not a satis-
factory procedure” should prompt clinicians to use
atherectomy more. Like all complex decision making,
multiple factors likely contribute to the ﬁndings in
our study, including patient-speciﬁc factors and
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these issues in the current study.
In conclusion, we agree with Dr. Carr that most
physicians work hard to improve the care of their
patients and make good clinical decisions. How-
ever, as seen in many aspects of medicine, the use of
more expensive treatment modalities in the absence
of evidence to support their use is often associated
with variation and should be examined. In the case
of PVI, we concluded that changes to the OPPS,
although designed to improve efﬁciency and reduce
costs, likely contributed to more use of atherectomy
and neutralization of cost savings to the Medicare
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Multivessel Primary PCI
The Debate ContinuesThe paper by Gershlick et al. (1) supports the concept
of coronary angioplasty of nonculprit lesions (NCLs)
at index admission based on visual assessment of
severity in patients presenting for primary percuta-
neous coronary intervention (P-PCI). This issue has
been debated for years.
It has been shown that only one-third of NCL-
associated events occur from angiographically signi-
ﬁcant NCLs, whereas two-thirds of events occur fromangiographically insigniﬁcant lesions or from normal
or nearly normal segments (2). NCL characteristics
associated with major adverse cardiac event were a
plaque burden of $70% and a minimal luminal area
of #4 mm2 and not angiographic severity alone.
Thus, ﬁxing all the visually signiﬁcant lesions at the
time of P-PCI may not be a prudent idea. Estimation of
NCL severity by fractional ﬂow reserve during the
acute phase of myocardial infarction (MI) is reliable
and may aid in intervening in ischemia-producing
lesions only (3).
Overestimation of NCL severity during acute MI is
well known (4), andmany of the apparently signiﬁcant
NCLs during the acute phase of MI may not require PCI
in follow-up therapy. It may be related to vascular
remodeling and healing of some of the NCLs over time.
Plaque passivation by medical therapy may diminish
slow ﬂow or no-reﬂow during PCI of NCLs, improve
myocardial perfusion, and favorably affect prognosis.
It would be interesting to know the lesion
morphology in 2 groups of this trial. Lesion charac-
teristics and anatomical variables may confound the
outcomes if not equally balanced in 2 groups. Stent
thrombosis after P-PCI is another cause for concern.
Acute vessel closure and stent thrombosis are re-
ported to be more frequent after multivessel PCI in a
highly prothrombotic environment of ST-segment
elevation MI with activated platelets and poor gas-
trointestinal absorption of clopidogrel.
With the current state of knowledge on this subject,
caution is required to translate these results into
clinical practice, when we see the articles suggesting
deferred stenting strategy for ST-segment elevation
MI (5) on one side of the spectrum and multivessel
stenting during P-PCI on the other.*Sanjeev K. Agarwal, MD, DM, CBCCT
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